- Home
- EIC vs YMAB Comparison
EIC vs YMAB Comparison
Compare EIC & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EIC
- YMAB
- Stock Information
- Founded
- EIC N/A
- YMAB 2015
- Country
- EIC United States
- YMAB United States
- Employees
- EIC N/A
- YMAB N/A
- Industry
- EIC Finance/Investors Services
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- EIC Finance
- YMAB Health Care
- Exchange
- EIC Nasdaq
- YMAB Nasdaq
- Market Cap
- EIC 287.1M
- YMAB 270.5M
- IPO Year
- EIC 2019
- YMAB 2018
- Fundamental
- Price
- EIC $14.94
- YMAB $4.95
- Analyst Decision
- EIC Strong Buy
- YMAB Buy
- Analyst Count
- EIC 1
- YMAB 11
- Target Price
- EIC $17.50
- YMAB $19.64
- AVG Volume (30 Days)
- EIC 301.0K
- YMAB 333.1K
- Earning Date
- EIC 02-20-2025
- YMAB 03-04-2025
- Dividend Yield
- EIC 16.42%
- YMAB N/A
- EPS Growth
- EIC N/A
- YMAB N/A
- EPS
- EIC 1.97
- YMAB N/A
- Revenue
- EIC $46,223,036.00
- YMAB $87,685,000.00
- Revenue This Year
- EIC $39.61
- YMAB $20.07
- Revenue Next Year
- EIC $27.28
- YMAB $8.76
- P/E Ratio
- EIC $7.44
- YMAB N/A
- Revenue Growth
- EIC 72.79
- YMAB 3.38
- 52 Week Low
- EIC $14.56
- YMAB $4.25
- 52 Week High
- EIC $16.75
- YMAB $17.78
- Technical
- Relative Strength Index (RSI)
- EIC 35.23
- YMAB 39.96
- Support Level
- EIC $14.51
- YMAB $4.45
- Resistance Level
- EIC $16.05
- YMAB $4.97
- Average True Range (ATR)
- EIC 0.27
- YMAB 0.35
- MACD
- EIC -0.09
- YMAB 0.05
- Stochastic Oscillator
- EIC 27.99
- YMAB 55.45
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.